Fintel reports that on September 12, 2024, Craig-Hallum upgraded their outlook for Champions Oncology (NasdaqCM:CSBR) from Hold to Buy. Analyst Price Forecast Suggests 52.62% Upside As of August 26, ...

The firm increased its portfolio allocation in CSBR by 1,586.70% over the last ... center of excellence to develop transformative technology and accelerate oncology research and development.

Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration ...

Champions Oncology , Inc. (NASDAQ: NASDAQ:CSBR), a research-driven company focused on developing advanced technology solutions and services to personalize the development and use of oncology drugs ...

Detailed price information for Champions Oncolog (CSBR-Q) from The Globe and Mail including charting and trades.

Exane BNP Paribas upgraded Bill (BILL) to Outperform from Neutral with a $90 price target. The company is investing in suppliers' go-to-market, which will generate sustainable take-rate expansion, the ...

I have found that being in the virtual environment allows our teachers, staff, and administrators to form meaningful ...

Champions Oncology Inc (CSBR) is expected to report $0.03 for ... Kewaunee Scientific (KEQU) is expected to report for 1Q. MIND Technology Inc (MIND) is expected to report $-0.01 for 2Q.

Champions Oncology (CSBR) surged more than +15% in pre-market trading after the company reported better-than-expected Q1 results. Micron Technology (MU) fell over -1% in pre-market trading after ...